Comparison of enzyme kinetic parameters obtained in vitro for reactions mediated by human CYP2C enzymes including major CYP2C9 variants

Curr Drug Metab. 2010 Feb;11(2):153-61. doi: 10.2174/138920010791110872.

Abstract

Cytochrome P450 (CYP) 2C enzymes contribute to the metabolism of about 30% of all drugs. Known polymorphisms of the respective enzymes and drug-drug interactions have a major impact on the efficacy and safety of some CYP2C substrate drugs. In vivo - in vitro correlations including prediction of the effect of such covariates requires quantitative information on enzyme kinetics. In this article there will be a summary of the values of the Michaelis-Menten constant (K(m)), the maximal velocity (V(max)) and the intrinsic clearance (Cl(int); V(max)/K(m)) for 84 substrates (100 reactions) reported to be mediated by CYP2C9 (variant enzymes CYP2C9.1, CYP2C9.2 and CYP2C9.3), CYP2C8 and/or CYP2C19. Particularly contradictory findings for the same reactions call for some standardization in the assessment of enzyme kinetics.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Aryl Hydrocarbon Hydroxylases / pharmacokinetics*
  • Aryl Hydrocarbon Hydroxylases / standards
  • Cytochrome P-450 CYP2C9
  • Drug Interactions / genetics
  • Genetic Variation / genetics*
  • Humans
  • Mixed Function Oxygenases / genetics*
  • Mixed Function Oxygenases / pharmacokinetics*
  • Mixed Function Oxygenases / standards
  • Polymorphism, Genetic
  • Substrate Specificity / genetics
  • Vitamin K Epoxide Reductases

Substances

  • Mixed Function Oxygenases
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Vitamin K Epoxide Reductases